Sharechat Logo

Synlait says Munchkin US FDA process on hold

Thursday 16th May 2019

Text too small?

Synlait Milk said the registration process required to launch Munchkin Inc’s Grass Fed infant formula in the US has been put on hold to allow the company to look at other options. 

Synlait "has been informed that the clinical study has been put on hold to allow Munchkin to explore other options in the US," it said. 

Synalit chief executive Leon Clement said Munchkin has not terminated its supply agreement with Synlait. "For other markets were Grass Fed is sold, the relationship continues with business as usual," he said.

Clement said the announcement will not have a material impact on Synlait's forecast infant formula volumes. In March it said it was on track to meet its full-year canned infant formula volume guidance of 41,000 – 45,000 metric tonnes, with significantly higher volumes forecast to be delivered in the second half of the financial year.

Synlait shares were unchanged at $10.20. 

The Synlait-Munchkin partnership was first announced in 2015 when Synlait teamed up with Munchkin to launch the new grass-fed brand into the US and China that would exclusively manufactured by Synlait.

In August 2017, it said the two companies were continuing to work through an FDA process that would take a further four to 12 months. The stringent process, known as a New Infant Formula Notification, includes a range of trials, audits and documentation.

(BusinessDesk)



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

RBNZ eyes Westpac Australia money laundering failures
Heritage buys Golden Healthcare; not mystery Metlife suitor
Alliance margins improve as swine fever boosts global meat prices
RBNZ eyes Westpac Australia money laundering failures
Precinct eyes new developments as Commercial Bay keeps to revised schedule
End to Tower's three year dividend drought in sight
Vital Healthcare's manager appoints new independent director
Argosy lifts first-half profit 15.2% on valuation gains
Metlifecare attracts 'credible' bidder after biggest trading day in 2 1/2 years
Serko to accelerate cash burn with North American push

IRG See IRG research reports